Wall Street analysts expect Mast Therapeutics, Inc. (NASDAQ:SVRA) to post earnings per share of ($0.23) for the current quarter, according to Zacks. Zero analysts have issued estimates for Mast Therapeutics’ earnings. Mast Therapeutics posted earnings of ($1.40) per share in the same quarter last year, which suggests a positive year over year growth rate of 83.6%. The firm is expected to announce its next earnings report on Monday, March 5th.
According to Zacks, analysts expect that Mast Therapeutics will report full-year earnings of ($1.66) per share for the current financial year, with EPS estimates ranging from ($1.71) to ($1.60). For the next financial year, analysts expect that the company will post earnings of ($1.26) per share, with EPS estimates ranging from ($1.40) to ($1.12). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Mast Therapeutics.
A number of analysts have weighed in on SVRA shares. Canaccord Genuity upped their target price on Mast Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Roth Capital restated a “buy” rating and set a $40.00 target price on shares of Mast Therapeutics in a report on Wednesday, September 27th. Jefferies Group LLC started coverage on Mast Therapeutics in a report on Friday, September 22nd. They set a “buy” rating and a $20.00 target price for the company. Finally, Zacks Investment Research upgraded Mast Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a report on Tuesday, September 19th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Mast Therapeutics currently has an average rating of “Buy” and an average price target of $21.30.
In other Mast Therapeutics news, Director Yuri Pikover acquired 50,000 shares of the firm’s stock in a transaction dated Friday, October 27th. The stock was purchased at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the acquisition, the director now owns 150,000 shares in the company, valued at approximately $1,177,500. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.93% of the stock is owned by corporate insiders.
Shares of Mast Therapeutics (NASDAQ SVRA) opened at $11.91 on Friday. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. Mast Therapeutics has a twelve month low of $4.60 and a twelve month high of $16.10.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/mast-therapeutics-inc-svra-expected-to-announce-earnings-of-0-23-per-share.html.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Get a free copy of the Zacks research report on Mast Therapeutics (SVRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.